IL143528A0 - Therapeutic agents containing botulinum toxin for the suppression of snoring noises - Google Patents

Therapeutic agents containing botulinum toxin for the suppression of snoring noises

Info

Publication number
IL143528A0
IL143528A0 IL14352899A IL14352899A IL143528A0 IL 143528 A0 IL143528 A0 IL 143528A0 IL 14352899 A IL14352899 A IL 14352899A IL 14352899 A IL14352899 A IL 14352899A IL 143528 A0 IL143528 A0 IL 143528A0
Authority
IL
Israel
Prior art keywords
bont
clostridium toxin
carrier
added
suppression
Prior art date
Application number
IL14352899A
Other languages
English (en)
Original Assignee
Biotecon Ges Fur Biotechnologi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Ges Fur Biotechnologi filed Critical Biotecon Ges Fur Biotechnologi
Publication of IL143528A0 publication Critical patent/IL143528A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
IL14352899A 1998-12-10 1999-12-10 Therapeutic agents containing botulinum toxin for the suppression of snoring noises IL143528A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19856897A DE19856897A1 (de) 1998-12-10 1998-12-10 Therapeutikum zur Unterdrückung von Schnarchgeräuschen
PCT/EP1999/009791 WO2000033863A2 (de) 1998-12-10 1999-12-10 Therapeutikum zur unterdrückung von schnarchgeräuschen

Publications (1)

Publication Number Publication Date
IL143528A0 true IL143528A0 (en) 2002-04-21

Family

ID=7890562

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14352899A IL143528A0 (en) 1998-12-10 1999-12-10 Therapeutic agents containing botulinum toxin for the suppression of snoring noises
IL143528A IL143528A (en) 1998-12-10 2001-06-03 Drugs that contain botulinum toxin to reduce snoring noise

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143528A IL143528A (en) 1998-12-10 2001-06-03 Drugs that contain botulinum toxin to reduce snoring noise

Country Status (21)

Country Link
US (1) US6573241B1 (da)
EP (1) EP1137430B1 (da)
JP (1) JP4700811B2 (da)
KR (1) KR100859556B1 (da)
CN (1) CN1186095C (da)
AT (1) ATE234108T1 (da)
AU (1) AU764744B2 (da)
BR (1) BR9915800A (da)
CA (1) CA2353469A1 (da)
CZ (1) CZ295769B6 (da)
DE (2) DE19856897A1 (da)
DK (1) DK1137430T3 (da)
ES (1) ES2192880T3 (da)
HK (1) HK1040636B (da)
HU (1) HUP0104702A3 (da)
IL (2) IL143528A0 (da)
NO (1) NO328762B1 (da)
PL (1) PL202908B1 (da)
PT (1) PT1137430E (da)
RU (1) RU2243783C2 (da)
WO (1) WO2000033863A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
CA2948238A1 (en) * 2005-06-14 2006-12-28 Revance Therapeutics, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
CN103315954A (zh) 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
MX2008006750A (es) 2005-12-01 2008-09-03 Univ Massachusetts Lowell Nanoemulsiones de botulinum.
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
WO2008140594A2 (en) * 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
BRPI0914630A2 (pt) * 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
WO2010078403A2 (en) * 2008-12-30 2010-07-08 Lipella Pharmaceuticals Inc. Methods and compositions for diagnosing urological disorders
WO2011057301A1 (en) * 2009-11-09 2011-05-12 Ira Sanders Treatment of sleep disordered breathing with neurotoxin
PL2677029T3 (pl) 2011-05-19 2017-10-31 Ipsen Bioinnovation Ltd Sposoby wytwarzania poddanych obróbce proteolitycznej polipeptydów
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
KR20180077343A (ko) 2012-11-21 2018-07-06 입센 바이오이노베이션 리미티드 단백질 가수분해 처리된 폴리펩티드의 제조방법
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551473A (en) * 1984-04-26 1985-11-05 Schossow George W Method of inhibiting snoring and obstructive sleep apnea
WO1994000481A1 (en) 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
CA2164626C (en) * 1993-06-10 2004-11-23 K. Roger Aoki Multiple botulinum toxins for treating neuromuscular disorders and conditions
EP1147776B1 (en) * 1993-12-28 2010-12-15 Allergan, Inc. Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US9316973B2 (en) 2013-06-13 2016-04-19 Lexmark International, Inc. Heat transfer system for a fuser assembly

Also Published As

Publication number Publication date
BR9915800A (pt) 2001-09-25
AU3037400A (en) 2000-06-26
JP4700811B2 (ja) 2011-06-15
DE19856897A1 (de) 2000-06-15
PL202908B1 (pl) 2009-08-31
ATE234108T1 (de) 2003-03-15
CA2353469A1 (en) 2000-06-15
RU2243783C2 (ru) 2005-01-10
HUP0104702A2 (hu) 2002-04-29
KR100859556B1 (ko) 2008-09-22
HK1040636B (zh) 2003-05-30
AU764744B2 (en) 2003-08-28
WO2000033863A3 (de) 2000-11-02
CN1186095C (zh) 2005-01-26
KR20010089527A (ko) 2001-10-06
NO20012716L (no) 2001-06-01
CN1329501A (zh) 2002-01-02
CZ295769B6 (cs) 2005-11-16
HK1040636A1 (en) 2002-06-21
WO2000033863A2 (de) 2000-06-15
CZ20012058A3 (cs) 2001-09-12
PL349334A1 (en) 2002-07-15
US6573241B1 (en) 2003-06-03
NO328762B1 (no) 2010-05-10
PT1137430E (pt) 2003-07-31
DE59904569D1 (de) 2003-04-17
JP2002531516A (ja) 2002-09-24
IL143528A (en) 2008-04-13
ES2192880T3 (es) 2003-10-16
NO20012716D0 (no) 2001-06-01
HUP0104702A3 (en) 2003-09-29
EP1137430B1 (de) 2003-03-12
DK1137430T3 (da) 2003-06-16
EP1137430A2 (de) 2001-10-04

Similar Documents

Publication Publication Date Title
IL143528A0 (en) Therapeutic agents containing botulinum toxin for the suppression of snoring noises
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
MX9706095A (es) Enzima multifuncional.
PL319833A1 (en) Compounds and composition for carrying active media
EP0921785A4 (en) COMBINATION OF ACID PROTEASE ENZYMES AND ACID BUFFERS AND THE USE THEREOF
BG100974A (en) Vaccines against papillomavirus
EP1820862A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
CA2191754A1 (en) Modification of Clostridial Toxins for Use as Transport Proteins
RU2001116080A (ru) Терапевтический агент для подавления шумов храпа
WO1998001158A3 (de) Hämoglobin-hydroxyethylstärke-konjugate als sauerstoff-transport-mittel
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
AU1436699A (en) The use of polyols in combating yeast infection and polyol preparations for saiduse
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU5956398A (en) Remedies for lymphocytic tumors
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
WO1996030042A3 (en) Methods of treating inflammation and compositions therefor
AU1041397A (en) Antigenic protein originating in malassezia
US5798392C1 (en) Sulfonyl fluorides for the treatment of alzheimer's disease
MXPA05003616A (es) Composiciones que comprenden anfotericina b altamente purificada.
GB2306885B (en) Supersaturated Pharmaceutical Compositions
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
IE840977L (en) Pharmaceutical preparations
DE69709891D1 (de) Chitosan enthaltende zusammensetzung
JPH053880B2 (da)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed